| Q37519488 | A functional polymorphism in the NKG2D gene modulates NK-cell cytotoxicity and is associated with susceptibility to Human Papilloma Virus-related cancers. |
| Q39187764 | Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility. |
| Q37408550 | Combination immune therapies to enhance anti-tumor responses by NK cells. |
| Q38014085 | Combination strategies to enhance antitumor ADCC. |
| Q89652991 | Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors |
| Q87854899 | Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack |
| Q24633763 | Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents |
| Q37821337 | Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect |
| Q41840058 | Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions |
| Q38940720 | Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia. |
| Q58750637 | NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy |
| Q38000961 | Prostate cancer and immunoproteome: awakening and reprogramming the guardian angels |
| Q38772095 | Role of NKG2D in cytokine-induced killer cells against lung cancer |
| Q39354030 | Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells |
| Q40521770 | STAT3 contributes to NK cell recognition by modulating expression of NKG2D ligands in adriamycin-resistant K562/AO2 cells |
| Q33829657 | Soluble major histocompatibility complex class I-related chain B molecules are increased and correlate with clinical outcomes during rhinovirus infection in healthy subjects |
| Q39611793 | Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells |
| Q39016695 | Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer |
| Q52657143 | Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates. |
| Q33825014 | Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway |
| Q36520715 | Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma |